0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > MICB

MICB

Brief Information

Name:MHC class I polypeptide-related sequence B
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
MIB-H52H3 Human Human MICB Protein, His Tag (MALS verified)
MIB-H52H3-structure
MIB-H52H3-sds
ACRO Quality

Part of Bioactivity data

MIB-H52H3-MALS-HPLC
MICB MALS images

The purity of Human MICB Protein, His Tag (Cat. No. MIB-H52H3) is more than 85% and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.

MIB-H52H3-ELISA
 MICB ELISA

Immobilized Human NKG2D Protein, Fc Tag (Cat. No. NKD-H5265) at 5 μg/mL (100 μL/well) can bind Human MICB Protein, His Tag (Cat. No. MIB-H52H3) with a linear range of 0.039-0.625 μg/mL (QC tested).

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CLN-619 CLN-619 Phase 1 Clinical PDI Therapeutics Inc Solid tumours Details
FT-536 FT-536 Phase 1 Clinical Fate Therapeutics Inc Ovarian Neoplasms; Solid tumours; Abdominal Neoplasms; Genital Neoplasms, Female; Fallopian Tube Neoplasms Details
DM-919 DM-919; DM919 Phase 1 Clinical D2M Biotherapeutics Inc Solid tumours; Neoplasms Details
CLN-619 CLN-619 Phase 1 Clinical PDI Therapeutics Inc Solid tumours Details
FT-536 FT-536 Phase 1 Clinical Fate Therapeutics Inc Ovarian Neoplasms; Solid tumours; Abdominal Neoplasms; Genital Neoplasms, Female; Fallopian Tube Neoplasms Details
DM-919 DM-919; DM919 Phase 1 Clinical D2M Biotherapeutics Inc Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop

Nachricht schicken